Nuvo is definitely one of the most undervalued stock in the US $ Canada Biotech Sector . Nuvo is almost a unknown Gem thats the only problem with this Goldmine but this will change soon with a US listing which will bring a lot of new investors to this Goldmine .

Nuvo has already 2 Products (Pennsaid +Synera) on the Market .The next Product (Pliaglis) will enter the US and EU Market by mid 2012 .Nuvo will get $ 8 M milestone payment upon EU launch from Top-Partner Galderma who holds the worldwide rights for Pliaglis .(MORE INFOS IN THEIR PRESENTATION LINK BELOW) .

Nuvo will be profitable by late 2012 or early 2013 the future looks very good for this Goldmine .

Market cap of 36 M is RIDICULOUS Nuvo deserves a Market cap of minimum $150 M or around 0.30 per share .

BUY WITH BOTH HANDS AT THIS PURE GIFT PRICE . PATIENCE WILL PAYOFF BIG TIME HERE .GLTA



Nuvo Research (NRI.TO) (NRIFF.PK) Canadian Stock

Market Cap : $36.6 M
Cash: $18.1 M
Price 0.065 $

NO DEBT



Presentation Jan 2012
http://www.nuvoresearch.com/investor...nuary_2012.pdf



Insider Activity
Latest Filings | Canadian Insider



LOTS OF GOOD NEWS COMING TO PUSH THIS GOLDMINE WAYY HIGHER ...

2012 Milestones

?? Growing Pennsaid U.S. sales = higher royalty revenue
?? Covidien sNDA for Pennsaid 2%
?? Pliaglis approval and launch in the U.S. and E.U. = new royalty
revenue and milestone payments
?? Relaunch Synera in the U.S. and expand in the E.U.
?? Announce action plan for WF10 development